Try a new search

Format these results:

Searched for:

in-biosketch:true

person:charvl01

Total Results:

182


Transcranial direct current stimulation (tdcs) results in lasting reduction in ms-related fatigue [Meeting Abstract]

Masters, L. Walton; Pilloni, G.; Muccio, M.; Ge, Y.; Krupp, L.; Charvet, L.
ISI:000596547102201
ISSN: 1352-4585
CID: 4737252

Manual dexterity improves with cognitive remediation in relapsing but not in progressive multiple sclerosis [Meeting Abstract]

Pilloni, G.; Shaw, M.; Sherman, K.; Krupp, L.; Charvet, L.
ISI:000596547102192
ISSN: 1352-4585
CID: 4737242

No difference in radiologic outcomes for natalizumab patients on extended interval dosing compared with standard interval dosing in ms paths [Meeting Abstract]

Zhovtis-Ryerson, L.; Naismith, R. T.; Krupp, L.; Charvet, L.; Su, R.; Fisher, E.; De Moor, C.; Williams, J.; Campbell, N.
ISI:000596547101134
ISSN: 1352-4585
CID: 4735892

Cognitive Impairment and MRI-based Disease Progression in MS PATHS: Variable Susceptibility Across the Lifespan [Meeting Abstract]

Charvet, Leigh; de Moor, Carl; Fitzgerald, Kathryn; Galioto, Rachel; Hersh, Carrie M.; Hua, Le; Hyland, Megan H.; Krupp, Lauren; Liao, Shirley; Montelban, Xavier; Mowry, Ellen M.; Nicholas, Jacqueline A.; Nos, Carlos; Rensel, Mary; Rao, Stephen; Rudick, Richard A.; Ryerson, Lana Zhovtis; Tinore, Mar; Ziemssen, Tjalf; Fisher, Elizabeth; Williams, James
ISI:000536058002171
ISSN: 0028-3878
CID: 4561272

Update on the Use of Transcranial Electrical Brain Stimulation to Manage Acute and Chronic COVID-19 Symptoms

Pilloni, Giuseppina; Bikson, Marom; Badran, Bashar W; George, Mark S; Kautz, Steven A; Okano, Alexandre Hideki; Baptista, Abrahão Fontes; Charvet, Leigh E
The coronavirus disease 19 (COVID-19) pandemic has resulted in the urgent need to develop and deploy treatment approaches that can minimize mortality and morbidity. As infection, resulting illness, and the often prolonged recovery period continue to be characterized, therapeutic roles for transcranial electrical stimulation (tES) have emerged as promising non-pharmacological interventions. tES techniques have established therapeutic potential for managing a range of conditions relevant to COVID-19 illness and recovery, and may further be relevant for the general management of increased mental health problems during this time. Furthermore, these tES techniques can be inexpensive, portable, and allow for trained self-administration. Here, we summarize the rationale for using tES techniques, specifically transcranial Direct Current Stimulation (tDCS), across the COVID-19 clinical course, and index ongoing efforts to evaluate the inclusion of tES optimal clinical care.
PMCID:7689057
PMID: 33281589
ISSN: 1662-5161
CID: 4703272

Using transcranial direct current stimulation to manage symptoms of multiple sclerosis

Chapter by: Shaw, Michael; Pilloni, Giuseppina; Charvet, Leigh
in: NEUROLOGICAL DISORDERS AND IMAGING PHYSICS, VOL 2: ENGINEERING AND CLINICAL PERSPECTIVES OF MULTIPLE SCLEROSIS by
pp. -
ISBN: 978-0-7503-1762-7
CID: 5353742

Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline

Wallach, Asya I; Waltz, Michael; Casper, T Charles; Aaen, Gregory; Belman, Anita; Benson, Leslie; Chitnis, Tanuja; Gorman, Mark; Graves, Jennifer; Harris, Yolanda; Lotze, Timothy E; Mar, Soe; Moodley, Manikum; Ness, Jayne M; Rensel, Mary; Rodriguez, Moses; Rose, John W; Schreiner, Teri; Tillema, Jan-Mendelt; Waubant, Emmanuelle; Weinstock-Guttman, Bianca; Charvet, Leigh E; Krupp, Lauren B
BACKGROUND/UNASSIGNED:Cognitive impairment occurs in approximately one-third of pediatric-onset multiple sclerosis (POMS) patients. The Symbol Digit Modalities Test (SDMT), a widely used cognitive screen in adults, has yet to be incorporated early into the standard care of POMS. OBJECTIVE/UNASSIGNED:To screen for cognitive impairment early in the course of POMS and analyze predictive factors. METHODS/UNASSIGNED:Of the 955 POMS or clinically isolated syndrome (CIS) patients prospectively assessed from March 2014 to July 2018, 500 POMS and 116 CIS patients met inclusion criteria (disease onset before the age of 18, one or more SDMTs, and 8 years or older at the time of testing). Those with relapse were analyzed separately from those who were relapse-free. RESULTS/UNASSIGNED: = 383, mean follow-up: 1.8 years), 14.1% had clinically meaningful decline predicted by older age of multiple sclerosis (MS) onset and male gender. Disease relapse or steroid use led to transient worsening on the SDMT. CONCLUSION/UNASSIGNED:Early in the disease, some POMS and CIS patients are at risk for cognitive impairment and subsequent decline.
PMID: 31775571
ISSN: 1477-0970
CID: 4216072

Long-term Cognitive Consequences for Patients With Pediatric-Onset Multiple Sclerosis

Krupp, Lauren B; Charvet, Leigh E
PMID: 31206137
ISSN: 2168-6157
CID: 3938902

Cognitive processing speed in pediatric-onset MS: Baseline characteristics of impairment and predictors of decline [Meeting Abstract]

Krupp, L; Wallach, A; Waltz, M; Casper, C; Aaen, G; Belman, A; Benson, L; Chitnis, T; Gorman, M; Graves, J; Harris, Y; Loetze, T; Mar, S; Moodley, M; Ness, J; Rensel, M; Rodriguez, M; Rose, J; Schreiner, T; Tillema, J -M; Waubant, E; Weinstock-Guttman, B; Charvet, L
Introduction: Cognitive impairment in pediatric onset multiple sclerosis (POMS) occurs in up to one third of cases.
Objective(s): To screen for cognitive impairment early in the disease course of POMS, measure predictive factors, and determine the effect of relapse on cognitive processing speed.
Aim(s): To identify cognitive processing speed impairment among POMS and pediatric clinically isolated (CIS) patients enrolled in the US Pediatric MS and Other Demyelinating Disease Registry. In March 2014, the Symbol Digit Modalities Test (SDMT) scores were analyzed from March 2014, when the SDMT was added to the clinical evaluation through July 2018, when the data set was locked.
Method(s): SDMT raw scores were converted to age-normative z-scores using validated age and sex adjusted means. Processing speed impairment was defined with z-score increments of-1.0. Clinically meaningful decline in longitudinal analyses was defined by a z-score decrease of 1.0 or more.
Result(s): For the POMS (n=500) and CIS (n=116) with at least one SDMT, the mean age at symptom onset was 13.5 years and the mean (+SD) disease duration at the initial SDMT assessment was 3.0 + 2.9 years. A total of 23.4% of MS and 16.4% of CIS patients had impaired processing speed at initial assessment. SDMT impairment was predicted by worse EDSS, longer disease duration, and lower level of mother's educational achievement. On longitudinal follow-up (n=383, mean follow-up: 1.8 years), 14.1% had clinically meaningful decline predicted by older age of MS onset, male gender, and longer test-retest interval. Disease relapse and steroid use were associated with transient SDMT worsening.
Conclusion(s): Early in the disease course, a subgroup of POMS patients are at risk for cognitive impairment and subsequent decline. Screening for cognitive slowing is critical for prompt identification of potential cognitive deficits and initiation of additional services
EMBASE:631450721
ISSN: 1352-4585
CID: 4385782

Telemedicine reaches MS patients living with disabilities: Athome telerehabilitation with remotely-supervised transcranial direct current stimulation (RS-tDCS) [Meeting Abstract]

Shaw, M; Best, P; Frontario, A; Lustberg, M; Sherman, K; Krupp, L; Charvet, L
Introduction: Travel to clinic can be difficult due to barriers of time and cost and becomes even more burdensome for MS patients living with disabilities. Telemedicine platforms present a solution by providing supervised treatment and rehabilitation at home. Without barriers to access, patients may be more compliant and adherent to daily rehabilitation exercises. We have a large telerehabilitation research program in MS that pairs rehabilitation with transcranial direct current stimulation (tDCS), an emerging non-invasive brain stimulation technique used to improve outcomes. We provide real-time treatment administration and supervision via HIPAA compliant videoconference, termed remotely supervised tDCS or RS-tDCS.
Objective(s): To characterize the advantages of telemedicine for patients with MS in an urban setting.
Aim(s): To measure barriers to access for participants in our RS-tDCS telerehabilitation program, as well as compliance and adherence to a remotely supervised intervention.
Method(s): Participants with MS were recruited to complete a trial of cognitive remediation paired with RS-tDCS at-home. Participants were surveyed following completion of the intervention and asked to rate their difficulty in attending the clinic (on a 1-5 ordinal scale, 1 = no difficulty and 5 = nearly impossible difficulty) as well as the typical cost of attending clinic. Descriptive statistics and ordinal logistic regression models were used to evaluate the factors driving difficulty of travel.
Result(s): Participants (n=44) reported that round trip travel to the clinic requires an average of 2.3+/-2.3 hours of time and $27.04+/-38.13. Participants rated the difficulty associated with attending clinic as being moderate to significant (2.5+/-1.3). Regression analyses that included disease features produced better models and accounted for greater variance in difficulty attending the clinic, (p< 0.001, McFadden pseudo R2 = .515), as compared with socioeconomic variables alone (p< 0.001, McFadden pseudo R2 = .140). The RS-tDCS protocol was successful in providing treatment (95% compliance to treatment) and 93% of participants reported satisfaction with the treatment and remote protocols.
Conclusion(s): Participants with MS face considerable difficulty reaching the clinic, largely due to increasing neurologic disability. Telemedicine techniques such as RS-tDCS can increase treatment access, reduce physical and financial burden of travel and maintain high rates of treatment adherence
EMBASE:631449568
ISSN: 1352-4585
CID: 4385812